IL-2 Clinical Trials

6 actively recruiting trials across 2 locations

Also known as: Aldesleukin, Cellular interleukin 2, interleukin-2

Pipeline

Phase 1: 3Phase 2: 1Phase 1/2: 2

Top Sponsors

Washington University School of Medicine1
TCRCure Biopharma Ltd.1
Sheba Medical Center1
Radboud University Medical Center1
Imugene Limited1

Indications

Cancer6
Malignant Melanoma Stage IV1
Tumor Associated Lymph Node T Cell1
Acute Myeloid Leukemia, Pediatric1
Aml1

Other4 trials

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Phase 2

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Phase 1

Natural Killer-cell Therapy for Acute Myeloid Leukemia

Phase 1/2

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

Phase 1

Gilbert, Arizona1 trial

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Banner MD Anderson Cancer Center

Phase 1

St Louis, Missouri1 trial

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Washington University School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.